MAQUET CARDIOVASCULAR RECEIVES FDA 510(K ) CLEARANCE AND CE MARK FOR ITS NEW SENSATION PLUS™ INTRA-AORTIC BALLOON CATHETER

MAQUET Cardiovascular, a leading provider of cardiovascular technologies, announced today that it has received both 510(k) clearance from the U.S. Food & Drug Administration (FDA) and CE mark approval for its new SENSATION PLUS™ 50cc 8 Fr. intra-aortic balloon catheter.

First Patients Enrolled in the U.S. OPEN Clinical Trial of the FlexStent(R) Femoropopliteal SE Stent System

Flexible Stenting Solutions Inc. has announced the successful treatment of the first two patients enrolled in the OPEN (Evaluation of Safety and Efficacy of the FlexStent(R) FemorOPopliteal Self-Expanding StENt System) clinical trial.

Baxter Announces FDA Approval of ARTISS Fibrin Sealant For Use in Face-Lift (Facial Rhytidectomy) Procedures

Baxter International Inc. has announced that FDA has expanded the indication of ARTISS [Fibrin Sealant (Human)] to include adhering tissue flaps during facial rhytidectomy surgery (face-lift)

MAQUET CARDIOVASCULAR RECEIVES FDA 510(K ) CLEARANCE AND CE MARK FOR ITS NEW SENSATION PLUS™INTRA – AORTIC BALLOON CATHETER

MAQUET Cardiovascular has announced that it has received both 510(k) clearance from the U.S. Food & Drug Administration (FDA) and CE mark approval for its new SENSATION PLUS™ 50cc 8 Fr. intra-aortic balloon catheter.

Spine Surgery Patient Brings Suit Against Medtronic, Inc. (MDT) for “Devastating Side Effects” From off label application of its Infuse Bone Graft Medical Device

Embattled medical device giant Medtronic Inc is feeling the heat again, as reported on www.devicespace.com.  This time it is alleged … continue reading “Spine Surgery Patient Brings Suit Against Medtronic, Inc. (MDT) for “Devastating Side Effects” From off label application of its Infuse Bone Graft Medical Device”

Abiomed Announces First Patient Enrolled In MINI-AMI FDA Study

Abiomed, Inc. has announced the first patient enrolled in MINI-AMI, an FDA prospective, randomized, controlled multi-center study to assess the role of 24-hours of direct unloading of the left ventricle with Impella(R) 2.5 support to reduce infarct size in patients with ST-elevation myocardial infarction without cardiogenic shock.

Most read

Latest

^